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ABSTRACT
Introduction: Approximately 30% of hepatitis C virus (HCV) monoinfected patients present 
persistently normal alanine aminotransferase (ALT) levels. Most of these patients have a slow 
progression of liver fibrosis. Studies have demonstrated the rate of liver fibrosis progression 
in hepatitis C virus-human immunodeficiency virus (HCV-HIV) coinfected patients is faster 
than in patients infected only by HCV. Few studies have evaluated the histological features of 
chronic hepatitis C in HIV-infected patients with normal ALT levels. Methods: HCV-HIV 
coinfected patients (HCV-RNA and anti-HIV positive) with known time of HCV infection 
(intravenous drugs users) were selected. Patients with hepatitis B surface antigen (HBsAg) 
positive or hepatitis C treatment before liver biopsy were excluded. Patients were considered 
to have a normal ALT levels if they had at least 3 normal determinations in the previous 6 
months prior to liver biopsy. All patients were submitted to liver biopsy and METAVIR scale 
was used. Results: Of 50 studied patients 40 (80%) were males. All patients were treated 
with antiretroviral therapy. The ALT levels were normal in 13 (26%) patients. HCV-HIV 
co-infected patients with normal ALT levels had presented means of the liver fibrosis stages 
(0.77±0.44 versus 1.86±1.38; p<0.001) periportal inflammatory activity (0.62±0.77 versus 
2.24±1.35; p<0.001) and liver fibrosis progression rate (0.058±0.043 fibrosis unit/year versus 
0.118±0.102 fibrosis unit/year) significantly lower as compared to those with elevated ALT. 
Conclusions: HCV-HIV coinfected patients with persistently normal ALTs showed slower 
progression of liver fibrosis. In these patients the development of liver cirrhosis is improbable. 
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RESUMO
Introdução: Aproximadamente, 30% dos portadores de hepatite crônica C apresentam níveis 
de aminotransferases persistentemente normais (APNL). A maioria destes pacientes tem 
lenta progressão da fibrose hepática. Em portadores de coinfecção VHC-HIV, estudos têm 
demonstrado que a progressão da fibrose hepática é mais rápida que a observada em indivíduos 
infectados somente pelo VHC. Há poucos estudos que verificaram as características histológicas 
da hepatite crônica C em pacientes coinfectados pelo HIV  APNL. Métodos: Portadores de 
coinfecção VHC-HIV (HCV-RNA e anti-HIV positivos) com tempo de infecção pelo VHC 
conhecido (uso de drogas intravenosas) foram selecionados. Aqueles com hepatitis B surface 
antigen (HbsAg) positivo ou que tenham sido submetidos à terapia antiviral para  hepatite 
C antes da biópsia hepática foram excluídos. Pacientes com pelo menos 3 determinações 
normais da ALT nos últimos 6 meses antes da biópsia hepática foram considerados como 
tendo APNL. Todos  foram submetidos a biópsia hepática que foi classificada de acordo com 
a escala METAVIR. Resultados: Foram incluídos 50 pacientes,  40 (80%) homens. Todos 
receberam terapia antirretroviral. Os níveis de ALT foram persistentemente normais em 13 
(26%) pacientes. Pacientes coinfectados com APNL apresentaram menor média dos estágiosde 
fibrose hepática (0,77±0,44 versus 1,86±1,38; p<0,001), dos índices de atividade inflamatória 
periportal (0,62±0,77 versus 2,24±1,35; p<0,001) e progressão mais lenta da fibrose hepática 
(0,058±0,043 unidades de fibrose /ano versus 0,118±0,102 unidades de fibrose/ano) quando 
comparados àqueles com aminotransferases elevadas. Conclusões: Portadores de coinfecção 
VHC-HIV com APNL apresentam progressão mais lenta da fibrose hepática. Nesses pacientes 
o desenvolvimento de cirrose hepática é improvável.
Palavras-chaves: Cirrose hepática. Hepatite C. HIV. Aminotransferases.
Due to shared risk factors for transmission of 
coinfection with human immunodeficiency virus 
(HIV) and hepatitis C virus (HCV) it is a very 
common event. It is estimated that around 30% of 
HIV-infected patients are coinfected with HCV in 
the United States and Europe1-7. The mode of HIV 
acquisition is directly associated with prevalence 
rates of HCV co-infection. Thus, the prevalence 
of HCV among men who have sex with men is 
approximately 10%, while 70-90% of the intravenous 
drugs users (IDU) are HCV co-infected1,8,9.
Liver disease caused by HCV is now the leading 
cause of morbidity and mortality among HIV-
infected patients in the developed world where 
classic severe immunodeficiency opportunistic 
infections have considerably declined as a result 
of the widespread use of potent antiretroviral 
therapy10-15.
Several  studies have demonstrated the 
deleterious HIV immunodeficiency action on the 
natural history of chronic hepatitis C. The rate of 
liver fibrosis progression in HCV-HIV coinfected 
patients is about 1.5 to 2 times faster than in 
patients infected only by HCV16-20. However, most 
of the studies were carried out during the pre-highly 
active antiretroviral therapy (HAART) era and 
only HCV-HIV coinfected patients with elevated 
aminotransferases levels were included, which may 
have overestimated the severity of the HCV induced 
liver disease.
The real effect of HAART on the natural history 
of chronic hepatitis C in HIV infected patients is 
still unclear.  Two studies reported that HCV-HIV 
coinfected patients submitted to HAART based on 
the use of protease inhibitors presented slower liver 
fibrosis progression21,22. Another study published 
by Qurish et al. found that HAART reduced liver 
related mortality in HCV-HIV coinfected patients23. 
On the other hand, Zylberberg et al described that 
the immunologic reconstitution after HAART 
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TABLE 1 - Comparative analysis of clinical characteristics between patients with normal and altered 
aminotransferases levels (n = 50).
 All Normal ALT  Altered ALT
 (n = 50) (n = 13) (n = 37)  
Variables n % n % n % P
Men 40 80.0 11 85.0 29 78.0 NS
Age at biopsy - years (mean ± SD) 38.5±6.6 38±7.8 39±6.2 NS
Age at HCV infection - years (mean ± SD) 21.5±7.9 22±8.4 21±7.8 NS
HCV infection duration - years (mean ± SD) 17.1±5.5 16±5.5 17±5.5 NS
Alcohol consumption > 50g/day 25 50.0 6 46.0 19 51.0 NS
Drug intravenous user 43 86.0 10 77.0 33 89.0 NS
HAART 41 82.0 11 85.0 30 81.0 NS
PI use  23 46.0 6 46.0 17 46.0 NS
ALT: alanine aminotransferase; SD: standard deviation; HCV: hepatitis C virus; HAART: highly active anti-retroviral therapy; 
PI: protease inhibitor; NS: not significant. 
TABLE 2 - Comparative analysis of biological parameters between patients with normal and altered 
aminotransferases levels (n = 50).
 All Normal ALT  Altered ALT
 (n = 50) (n = 13) (n = 37)  
Variables n % n % n % P
CD4 count - cells/mm3 (mean ±SD) 424.3±234.4 472±332 407±191 NS
HIV viral load - copies/mm3 (mean ±SD) 13.451±28.452 14.016±17.808 12.847±31.556 NS
CD4 count > 200cells/mm3 42 84.0 11 85.0 31 84.0 NS
HIV viral load < 400/copies  24 48.0 5 38.0 19 51.0 NS
HCV genotype* non-1  28/43 65.0 10 77.0 18 48.0 0.11
ALT: alanine aminotransferase; CD4: cluster of differentation; SD: standard deviation; HIV: human immunodeficiency virus; 
HCV: hepatitis C virus; *n=43; NS: not significant.  
accelerated progression of chronic hepatitis C to more advanced 
liver fibrosis stages24 and Antonello et al reported that coinfected 
patients showed a higher aspartate aminotransferase to platelet ratio 
index (APRI), a noninvasive liver fibrosis marker, after six months of 
HAART when compared with hepatitis C monoinfected patients25. 
Approximately 30% of chronic hepatitis C carriers present 
persistently normal alanine aminotransferase (ALT) levels. Most 
of these patients show mild histological lesions and have slow liver 
fibrosis progression26,27. Prospective studies and outcome modeling 
projections suggest that the risk of liver disease progression towards 
severe fibrosis/cirrhosis is minimal at 10-15 years in hepatitis C virus 
carriers with persistently normal ALT28.
In the world, few studies have evaluated the behavior of chronic 
hepatitis C in HIV-infected patients with normal aminotransferases 
levels29-31. In HCV-HIV coinfected Brazilian patients, the prevalence of 
individuals with normal aminotransferases levels, the rate of liver fibrosis 
progression and their histological characteristics, remain to be studied.
From June 2001 to June 2004, there were, HCV-HIV coinfected 
patients followed in Federal University of São Paulo, Brazil, based 
on serum antibody detection with a third generation enzyme-
linked immunosorbent assay. Serum HCV-RNA was detected 
by qualitative polimerase chain reaction (PCR-Amplicor; Roche 
Diagnostic Systems). Only patients with known HCV infection 
duration were selected. The HCV infection onset was considered as 
the first year of intravenous drugs usage, or transfusion. Exclusion 
criteria: presence of hepatitis B surface antigen (HBsAg) or hepatitis 
C treatment before liver biopsy. Patients were considered to have 
normal ALT if they had at least 3 normal determinations (lower 
than the upper limit of normal) in the previous 6 months prior to 
liver biopsy were included in Group 1 (G1). Patients with altered 
aminotransferases levels were included in Group 2 (G2). All patients 
were submitted to liver biopsy independent of ALT levels. Using 
METAVIR classification, a single experienced pathologist performed 
the histological evaluation. The fibrosis progression rate (FPR) was 
defined as the ratio between the fibrosis stage and HCV infection 
duration (fibrosis units/year). To calculate the time required until 
the development of cirrhosis was divided 4 (F4 = cirrhosis) by the 
fibrosis progression rate in fibrosis units/year. Advanced liver fibrosis 
and intense inflammatory activity was considered when they are ≥ 2.
Statistical analyses
Quantitative variables were expressed as average ± standard 
deviation (SD) and were compared using the Student´s t-test. 
Percentages were compared using c2 test and Fisher´s exact test when 
appropriate. A difference was considered significant if the P-value was 
less than 0.05. The Statistical Package for the Social Sciences (SPSS) 
software package version 10 (SPSS Inc., Chicago, IL) was used.
Ethical considerations
The study was approved by the Research Ethics Committee of the 
São Paulo Hospital of the Federal University of São Paulo.
Seventy-nine patients with positive antibody anti-HCV and 
HCV infection with known duration were selected. Three of these 
were excluded by presenting the HBsAg, four due to the absence of 
HCV-RNA, and 22 patients for loss of the pursuing or refusing the 
liver biopsy. Then, 50 patients were included. 
The average age at liver biopsy was 38±6.6 
years and 40 (80%) were males. The use of 
intravenous drugs was considered the virus 
acquisition mode in 43 (86%) patients. All 
patients were treated with antiretroviral 
therapy and 82% of them used HAART 
(Table 1). The cluster of differentiation 
(CD4) cell count was above 200 cells/mm3 in 
84% of patients and the HIV viral load was less 
than 400 copies/mm3 in 48% of the sample 
(Table 2). The ALT levels were considered 
normal in 13 (26%) patients. Advanced liver 
fibrosis (fibrosis stage ≥ 2) and inflammatory 
activity ≥ 2 were identified in 36% and 54% of 
the sample, respectively (Table 3).
Regarding ALT levels, both of groups 
showed similar demographic characteristics 
and alcohol consumption (Table 1). In 
addition, the immunological parameters 
related to HIV infection and genotype 
distribution were not different between two 
groups (Table 2).
With respect to histological findings, 
the HCV-HIV co-infected patients with 
normal ALT levels had an average of the liver 
fibrosis stages (0.77±0.44 versus 1.86±1.38; 
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TABLE 3 - Comparative analysis of histological findings between patients with normal and altered 
aminotransferases levels (n = 50).
                     Normal ALT     Elevated ALT
                     (n=13)                      (n=37)
Variables   n % n % P
Liver fibrosis stage (mean ± SD) 0.77±0.44 1.86±1.38 < 0.0001
Inflammatory activity (mean ± SD) 0.62±0.77 2.24±1.35 < 0.0001
FPR (mean ± SD) 0.058±0.043 0.118±0.102 0.006
Fibrosis stage > 2 (n/%) 0 0.0 18 49.0 0.002
Inflammatory activity > 2 (n/%) 2 15.0 25 68.0 < 0.0001
ALT: alanine aminotransferase; SD: standard deviation; FPR: fibrosis progression rate in units fibrosis/year.
p<0.001) and periportal inflammatory 
activ ity (0.62±0.77 versus  2.24±1.35; 
p<0.001) significantly lower when compared 
to HCV-HIV coinfected patients with altered 
aminotransferases levels. None of the patients 
with normal ALT levels had advanced liver 
fibrosis stages. Only two (15%) patients of 
group 1 had severe inflammatory activity. 
Furthermore, HCV-HIV co-infected patients 
with normal aminotransferases levels showed 
significantly lower liver fibrosis progression 
rates (0.058±0.043 fibrosis unit (FU)/year versus 0.118±0.102 
FU/year) when compared to patients from group 2 (Table 3). The 
interval between HCV infection and development of liver cirrhosis 
(F4), assuming that the fibrosis progression rate is linear, it was 69 
(F4/0.058) and 34 years (F4/0.118) for groups 1 e 2, respectively 
(Figure 1).
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FIGURE 1 - Estimated time to the development of liver cirrhosis according to 
the ALT levels (n = 50).
ALT: alanine aminotransferase.
DISCUSSION
In healthy patients the normal range for serum ALT level was set 
in the 1955 by Karmen32 and has changed little since then. Current 
upper limit of normality (ULN) were set, on average, from 30 to 
50U/L. This was recently challenged by a research group, who 
claimed that the true normal values are significantly lower. Prati et 
al suggested that the updated upper limit of normality of alanine 
aminotransferase should be 30U/L for males and 19U/L for females 
in subjects with the lowest risk for liver disease33.
In chronic hepatitis C patients the definition of persistently 
normal ALT activity (PNALT) no has consensus. Guidelines from 
the American Association for the Study of Liver Disease suggest 
that at least two ALT measurements within the normal range taken 
over at least 6 months can define those with PNALT34. Fonquernie 
et al. considered PNALT coinfected patients with normal ALT levels 
documented by repeated testing (at least three values per year) over a 
3-year period29. A French study by Bani-Sadr et al, coinfected patients 
with persistently normal ALT levels were defined as those having 
three consecutive persistently normal ALT levels over a 6-month 
period30 the same criteria adopted in this study.
Although chronic HCV infection is associated with elevation 
of ALT activity in most patients, approximately 25% presented 
serum ALT activity that is persistently within the normal range35. 
Fonquernie et al. reported among 155 HCV-HIV coinfected patients, 
39 (28.5%) had persistently normal ALT levels29. In study involving 
381 HCV-HIV coinfected patients, Bani-Sadr et al. identified 36 
(9.4%) subjects with persistently normal ALT values30. Sanchez-
Conde et al. reported 24/256 (9.4%) HIV-HCV coinfected patients 
with persistently normal ALT levels31. In the present study, we found 
13/50 (26%) coinfected patients on HAART with persistently 
normal aminotransferases levels. The variable criteria of PNALT 
used among several studies may explain the different prevalence 
rates observed.
In chronic hepatitis C, comparisons between normal and elevated 
ALT patients have not identiﬁed clear differences that could be used 
as ALT level predictive factors. In this study, there was a tendency 
to genotype non-1 in patients with altered aminotransferases levels 
(9% versus 44%; p=0.06). In the Sanchez-Conde study, patients 
infected with HCV genotype 3 were significantly more common 
between patients with altered ALT levels than in patients with 
persistently normal ALT levels31. In the Bani-Sadr study, a lower mean 
METAVIR inflammation score, the absence of steatosis and HCV 
genotype 4 were associated with persistently normal ALT levels30. 
In the Fonquernie study, three factors associated with persistently 
normal ALT levels were identified, namely: HBsAg negativity, HCV 
genotype 4 and female sex29.
The natural history of chronic hepatitis C is variable. Since 
most patients with HCV-related chronic hepatitis do not develop 
cirrhosis, it is logical to infer that host-related and virus-related 
factors must play a role in the progression to cirrhosis. Liver disease 
progression takes place over several decades, and is accelerated in the 
presence of cofactors such as alcohol consumption, insulin resistance, 
steatosis, older age of acquisition and HIV coinfection. Definition 
of histological features and liver disease progression in individuals 
with HCV and normal ALT is complicated because the absence of 
a gold standard definition for PNALT. Nevertheless, it is generally 
accepted that individuals with PNALT have milder liver histology 
when compared to patients with elevated aminotransferases levels36,37.
Most studies have shown that in HCV-HIV coinfected patients 
liver fibrosis progression is faster than in HCV monoinfected 
patients16-20. There are few studies that analyze liver histology in 
HIV-HCV coinfected patients with PNALT. In this study, individuals 
with normal aminotransferase levels showed mild histological lesions 
and slower liver fibrosis progression. In the Bani-Sadr study, none of 
the 36 patients with PNALT had cirrhosis30. In coinfected patients 
with normal aminotransferases levels Fonquernie et al demonstrated 
a significantly lower fibrosis score and fibrosis progression rate29. 
In this study, factors known to be related to the progression of 
chronic hepatitis C in monoinfected patients such gender, alcohol 
consumption and age at time of infection were similar in both groups. 
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